相关临床试验
3
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1998
暂无试验阶段数据
进行中（未招募）
1
33.3%
已完成
1
33.3%
终止
1
33.3%
暂无批准数据
- The Multiple Myeloma Research Foundation presented 23 research abstracts at the 22nd International Myeloma Society Annual Meeting, including five direct presentations and 18 studies based on their flagship programs. - Key findings from the MyDRUG precision medicine trial demonstrated how daratumumab-based quadruplet therapy reshapes T cell populations in bone marrow, highlighting immune function's critical role in current therapies. - The Immune Atlas program revealed how the immune system changes during multiple myeloma treatment through longitudinal multi-omic profiling that uncovers immune escape mechanisms and response predictors. - MMRF's research initiatives have contributed to tripling life expectancy for multiple myeloma patients, with the foundation having raised over $600 million for research and helped bring 15+ FDA-approved therapies to market.
- The Multiple Myeloma Research Foundation (MMRF) has initiated its Horizon Clinical Trials Program, enrolling the first patient in a study of relapsed and refractory myeloma. - The adaptive platform trial, conducted across the MMRC, will assess multiple novel therapies to determine optimal treatment strategies for myeloma patients. - The first arm of the Horizon trial will evaluate dosing approaches with teclistamab, aiming to refine treatment protocols for improved patient outcomes. - The Horizon program is designed to accelerate the development of precise treatments through flexible, multi-arm testing of different therapies.
